BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Mark A. Sirgo sold 162,509 shares of the business’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $2.78, for a total value of $451,775.02. Following the completion of the sale, the director now owns 1,759,262 shares of the company’s stock, valued at approximately $4,890,748.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
BioDelivery Sciences International, Inc. (BDSI) traded up $0.12 during trading hours on Friday, hitting $2.70. The stock had a trading volume of 532,970 shares, compared to its average volume of 599,860. The firm has a market capitalization of $150.89, a price-to-earnings ratio of 30.00 and a beta of 0.74. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.07 and a current ratio of 1.28. BioDelivery Sciences International, Inc. has a 1-year low of $1.55 and a 1-year high of $3.60.
BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.01. The business had revenue of $11.25 million for the quarter, compared to analyst estimates of $9.40 million. BioDelivery Sciences International had a return on equity of 33.83% and a net margin of 10.40%. The company’s revenue for the quarter was up 215.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.30) earnings per share. analysts expect that BioDelivery Sciences International, Inc. will post 0.16 earnings per share for the current fiscal year.
BDSI has been the topic of a number of recent research reports. Roth Capital set a $5.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a report on Monday, November 13th. Cantor Fitzgerald set a $5.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a report on Thursday, October 12th. HC Wainwright set a $5.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a report on Friday, October 13th. Finally, Piper Jaffray Companies set a $4.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a report on Sunday, October 22nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $4.29.
WARNING: “BioDelivery Sciences International, Inc. (BDSI) Director Sells $451,775.02 in Stock” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/19/biodelivery-sciences-international-inc-bdsi-director-sells-451775-02-in-stock.html.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.